Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Carcinoma, Renal Cell 27Neoplasms 9Neoplasm Metastasis 9Breast Neoplasms 9Kidney Neoplasms 6Prostatic Neoplasms 4Gastrointestinal Stromal Tumors 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms by Histologic Type 3Melanoma 3Liver Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Primary Myelofibrosis 2Neuroendocrine Tumors 2Neoplasms, Glandular and Epithelial 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Digestive System Neoplasms 2Clear-cell metastatic renal cell carcinoma 2

Interventions

Cyclophosphamide 14fludarabine phosphate 13ruxolitinib 9Busulfan 9Antilymphocyte Serum 9fludarabine 8Peripheral Blood Stem Cell Transplantation 8Filgrastim 8Whole-Body Irradiation 7Cyclosporine 7Tacrolimus 6Radiotherapy 6Mycophenolic Acid 6Methylprednisolone 6Methotrexate 5Melphalan 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Azacitidine 5Imatinib Mesylate 4Alemtuzumab 4ponatinib 3parsaclisib 3fedratinib 3Stem Cell Transplantation 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Decitabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myeloproliferative Disorders × Sunitinib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡